GSA Capital Partners LLP Invests $95,000 in Adaptimmune Therapeutics plc (NASDAQ:ADAP)

GSA Capital Partners LLP acquired a new stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 99,662 shares of the biotechnology company’s stock, valued at approximately $95,000.

A number of other large investors have also recently added to or reduced their stakes in ADAP. Long Focus Capital Management LLC increased its holdings in shares of Adaptimmune Therapeutics by 15.6% in the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after acquiring an additional 1,662,184 shares during the last quarter. Renaissance Technologies LLC increased its stake in Adaptimmune Therapeutics by 28.3% during the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after purchasing an additional 394,566 shares during the last quarter. Vontobel Holding Ltd. raised its holdings in shares of Adaptimmune Therapeutics by 230.8% during the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 30,000 shares during the period. Finally, Fullcircle Wealth LLC bought a new position in shares of Adaptimmune Therapeutics in the 3rd quarter worth about $33,000. 31.37% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics Trading Up 5.4 %

Shares of NASDAQ:ADAP opened at $0.70 on Tuesday. The company has a 50 day moving average price of $0.83 and a 200 day moving average price of $1.01. The stock has a market capitalization of $178.37 million, a price-to-earnings ratio of -3.17 and a beta of 2.26. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics plc has a 1-year low of $0.42 and a 1-year high of $2.05.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ADAP shares. Guggenheim decreased their target price on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. HC Wainwright decreased their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, StockNews.com downgraded Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Adaptimmune Therapeutics currently has an average rating of “Buy” and a consensus target price of $3.16.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.